GLP1_NEW
Safiglipron (HRS-7535) 15 mg tablet once daily
SAFIGL_PO_15MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.64 (0.01 to 50.16) | 0.44 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.67 (0.01 to 44.80) | 0.54 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.14 (0.00 to 1.77) | 0.86 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 5.94 (0.92 to 39.19) | 0.19 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.53 (0.33 to 5.28) | 0.65 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.85 (0.12 to 14.19) | 0.58 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.93 (0.57 to 11.26) | 0.30 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.03 (0.33 to 27.67) | 0.32 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.85 (0.05 to 13.75) | 0.47 |